-+ 0.00%
-+ 0.00%
-+ 0.00%

Chemomab Reports Data From Two Study abstracts To Be Presented At Annual Congress of the European Association for the Study of the Liver May 7-10

Benzinga·04/28/2025 12:02:45
Listen to the news

New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers

Further Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Other Fibro-Inflammatory Conditions

Second EASL 2025 Poster Reports that Pharmacokinetic and Pharmacodynamic Data from the Phase 2 Spring Trial Demonstrates Effective and Dose-Dependent Antibody-Target Engagement